Enthorin and Rumi sign agreement for FXS therapy
Rumi Therapeutics will take over the development of the compound, renaming it RTX-7340.
Drug Development
Formation Bio launches $600m drug development fund
FDA grants orphan drug status to Octant’s OCT-980 for RP
Arrowhead gains UK marketing authorisation for Redemplo
Regeneron agrees to $270m extension to supply Ebola medicine in US
China’s NMPA accepts Innovent application for sintilimab combo
Lunit and Summit to evaluate pathology platform for tumour analysis
Pathos AI completes $237m Series E round to expand oncology pipeline
